GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

TaiwanJ Pharmaceuticals Co 6549.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

6.25

+3.48%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About TaiwanJ Pharmaceuticals Co

Its shares trade on Taipei Exchange under the ticker 6549.TWO. It has been listed since 21 October 2015. In the fiscal year to 31 December 2023, it reported revenue of TWD 22.7m and a net loss of TWD 6.0m. At that date it held total assets of TWD 73.6m and shareholders' equity of TWD 66.9m.

TaiwanJ Pharmaceuticals Co., Ltd. engages in new medical research activities. The company is headquartered in Zhubei, Hsinchu. The company went IPO on 2015-10-21. The firm is specialized in early research of new drugs and development of clinical drugs. The firm's products are used for the treatment of chronic liver diseases. The firm is in the development stage and not generating any revenue.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
21 Oct 2015
Website
taiwanj.com ↗

Leadership

Pay as last reported

  • Ms. Ying-Chu ShihChairman of the Board, since 2018
  • Mr. Hung-Chang YuanGeneral Manager, Director, since 2016
  • Mr. Syau Lan YangDeputy General Manager
  • Zhijie GuoHead of Finance & Accounting
  • Mr. Weicheng CaiDirector
  • Jiarong LiDirector
  • Qinghua YangDirector
  • Xiuqing GaoIndependent Director
  • Rongsheng SuIndependent Director
  • Mingyuan ZhengIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • TaiwanJ Pharmaceuticals focuses on early drug research for chronic liver diseases.
  • The company's biotechnology expertise supports innovative drug development.
  • Headquartered in Zhubei, Hsinchu, it benefits from a strong biotech hub.

Weaknesses

  • The firm is in the development stage without generating any revenue.
  • No revenue stream indicates limited commercialization progress.
  • Early research phase delays potential market entry and profitability.

Opportunities

  • Growing demand for chronic liver disease treatments in Asia.
  • Biotechnology sector expansion in Taiwan offers new partnerships.
  • Potential for clinical drug development to address unmet medical needs.

Threats

  • Competition from established biotech firms in the Health Care sector.
  • Regulatory hurdles in drug development could delay approvals.
  • Economic downturns may impact funding for early-stage research.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.